BTK and B-cell chronic lymphocytic leukemia: Consequently, CLL patients receiving BTK inhibitor therapy have become an even more attractive target for T cell based immunotherapies, whereas classic chemoimmunotherapy regimes like the ones the patients in our study received, have considerably lost their clinical relevance.